Changes in Successive Measures of De Novo Donor-Specific Anti–Human Leukocyte Antigen Antibodies Intensity and The Development of Allograft Dysfunction

Abstract

Our study suggests that tracking dnDSA intensity, particularly in the early period after onset, is important to estimate the impact of dnDSA on the allograft and could, therefore, determine help on how best to monitor patients with dnDSA.